Go Pro

Enliven Therapeutics (ELVN) Insider Trading & Ownership

Enliven Therapeutics logo
$50.74 -0.12 (-0.23%)
Closing price 06/30/2026 03:59 PM Eastern
Extended Trading
$50.71 -0.02 (-0.05%)
As of 06/30/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
3.00%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
6
Amount Of
Insider Selling
(Last 12 Months)
$10.53M
Get ELVN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ELVN Insider Buying and Selling by Quarter

Enliven Therapeutics Insider and Congressional Trades History

Transaction DateInsiderBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/17/2026Sell6,018$43.80$263,588.40  
6/5/2026Sell10,000$34.54$345,400.00  
3/6/2026Sell10,000$29.58$295,800.00  
2/17/2026Sell1,230$26.18$32,201.40  
2/6/2026Sell5,000$29.04$145,200.00  
1/20/2026Sell20,000$26.75$535,000.00  
1/20/2026Sell1,230$26.75$32,902.50  
1/9/2026Sell48,300$27.99$1,351,917.00  
1/9/2026Sell91,198$27.22$2,482,409.56  
1/9/2026Sell4,285$25.00$107,125.00  
Do NOT Buy SpaceX – Do This Instead (Ad)

SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel

Read Tilson's free analysis and find out what to do with your money
1/8/2026Sell41,302$24.05$993,313.10  
1/8/2026Sell9,635$25.03$241,164.05  
12/19/2025Sell5,000$16.84$84,200.00  
12/8/2025Sell6,663$21.02$140,056.26  
11/19/2025Sell12,500$22.33$279,125.00  
11/17/2025Sell12,500$21.82$272,750.00  
11/7/2025Sell6,667$17.40$116,005.80  
10/20/2025Sell12,500$22.08$276,000.00  
10/17/2025Sell12,500$21.33$266,625.00  
10/7/2025Sell6,667$20.10$134,006.70  
9/29/2025Sell3,250$20.40$66,300.00  
9/26/2025Sell4,000$20.25$81,000.00  
9/26/2025Sell3,700$20.06$74,222.00  
9/23/2025Sell1,500$20.03$30,045.00  
9/23/2025Sell2,800$20.03$56,084.00  
9/19/2025Sell7,000$19.39$135,730.00  
9/19/2025Sell1,000$20.25$20,250.00  
9/17/2025Sell5,000$19.09$95,450.00  
9/8/2025Sell6,667$20.24$134,940.08  
8/27/2025Sell3,250$20.63$67,047.50  
8/21/2025Sell7,500$20.01$150,075.00  
8/19/2025Sell5,000$19.62$98,100.00  
8/19/2025Sell590$20.00$11,800.00  
8/18/2025Sell10,393$20.02$208,067.86  
8/7/2025Sell6,667$18.24$121,606.08  
7/28/2025Sell3,250$20.46$66,495.00  
7/21/2025Sell12,500$22.29$278,625.00  
7/17/2025Sell12,500$22.52$281,500.00  
7/10/2025Sell1,000$22.66$22,660.00  
7/7/2025Sell6,667$19.79$131,939.93  
Do NOT Buy SpaceX – Do This Instead (Ad)

SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel

Read Tilson's free analysis and find out what to do with your money
(Data available from 1/1/2013 forward)

ELVN Insider Trading Activity - Frequently Asked Questions

The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Lori Anne Kunkel, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN.

3.00% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings.

The following insiders have sold ELVN shares in the last 24 months: Anish Patel ($4,558,388.38), Benjamin Hohl ($2,475,312.01), Joseph P Lyssikatos ($8,570,951.75), Lori Anne Kunkel ($345,400.00), Rahul D Ballal ($293,531.40), Richard A Heyman ($672,870.84), and Samuel Kintz ($3,806,061.06).

Insiders have sold a total of 853,324 Enliven Therapeutics shares in the last 24 months for a total of $20,722,515.44 sold.



This page (NASDAQ:ELVN) was last updated on 7/1/2026 by MarketBeat.com Staff.
From Our Partners